Multiple Sclerosis Disease‐Modifying Therapies in the COVID‐19 Era

Emerging Therapies in Multiple Sclerosis

Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis.

BACKGROUND Currently available disease-modifying therapies (DMTs) are known to be only partially effective in adults with multiple sclerosis (MS). Little is known about pediatric patients with MS who experience refractory disease while receiving first-line DMTs. OBJECTIVE To assess the occurrence and management of refractory disease in a group of pediatric patients with MS treated with first-...

Emerging Therapies of Multiple Sclerosis

5. Monoclonal Anti body Multi ple sclerosis (MS) is a complex immunopathologic disorder of the central nervous system (CNS). For the past several years, there have been six agents approved by regulatory agencies to treat relapsing forms of multi ple sclerosis (MS): interferon beta-1b, intramuscular interferon beta-1a, subcutaneous interferon beta-1a, glati ramer acetate, natalizumab, and mitoxa...

Emerging multiple sclerosis oral therapies.

Currently, patients suffering from multiple sclerosis (MS), a chronic demyelinating disorder of the CNS, must be injected with medication to provide modest relief for their symptoms. Five orally available therapies are being evaluated in phase II/III clinical trials. If these therapies prove safe and tolerable, oral compounds may improve patient endorsement and compliance. Fingolimod, a novel i...

Using stem cells in multiple sclerosis therapies.

Stem cell transplantation approaches offer for the first time the opportunity to design therapeutic approaches for multiple sclerosis (MS) with curative intent. Here we discuss key observations and questions emerging from clinical trials of hematopoietic stem cell transplantation for MS and from studies of myelin/neural repair in experimental models of demyelinating disorders.